Stanford Spinout Carmenta Bioscience Prepping Validation Study of Preeclampsia Protein Dx | GenomeWeb

Maternal and fetal biomarker firm Carmenta Bioscience said last week it has acquired an option for a global, exclusive license from Stanford University for preeclampsia biomarkers that it plans to develop into a diagnostic panel for the condition.

The company, which was co-founded by Stanford researchers Atul Butte and Bruce Ling, is currently working to put together a several-hundred-patient clinical trial that it hopes to launch sometime this year to test the markers, CEO Matthew Cooper told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: parent-of-origin effects, framework to uncover clinically important mutations from whole genome sequence data, and more.

A survey of Cincinnati schoolchildren finds teenagers want to know their genetic predisposition to disease, LiveScience reports.

More and more universities are helping their researchers patent their inventions, the Los Angeles Times reports.

Cancer Research UK unveils seven 'grand challenges' that it will fund researchers to tackle.

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Sponsored by

This webinar will focus on a range of research and clinical applications enabled by improvements in mate pair technology for whole genome sequencing. 

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.